Advisory Alpha LLC Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Advisory Alpha LLC boosted its position in shares of Pfizer Inc. (NYSE:PFEGet Rating) by 38.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,097 shares of the biopharmaceutical company’s stock after purchasing an additional 4,723 shares during the period. Advisory Alpha LLC’s holdings in Pfizer were worth $1,010,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in PFE. Abbrea Capital LLC grew its holdings in shares of Pfizer by 0.4% in the fourth quarter. Abbrea Capital LLC now owns 91,437 shares of the biopharmaceutical company’s stock valued at $5,399,000 after purchasing an additional 360 shares in the last quarter. Legacy Financial Advisors Inc. grew its holdings in shares of Pfizer by 5.8% in the fourth quarter. Legacy Financial Advisors Inc. now owns 39,786 shares of the biopharmaceutical company’s stock valued at $2,349,000 after purchasing an additional 2,183 shares in the last quarter. Pictet North America Advisors SA grew its holdings in shares of Pfizer by 16.5% in the fourth quarter. Pictet North America Advisors SA now owns 8,475 shares of the biopharmaceutical company’s stock valued at $500,000 after purchasing an additional 1,200 shares in the last quarter. Ruffer LLP grew its holdings in shares of Pfizer by 28.6% in the fourth quarter. Ruffer LLP now owns 559,354 shares of the biopharmaceutical company’s stock valued at $31,757,000 after purchasing an additional 124,464 shares in the last quarter. Finally, Delta Financial Advisors LLC grew its holdings in shares of Pfizer by 3.0% in the fourth quarter. Delta Financial Advisors LLC now owns 45,564 shares of the biopharmaceutical company’s stock valued at $2,691,000 after purchasing an additional 1,315 shares in the last quarter. 64.96% of the stock is currently owned by institutional investors and hedge funds.

NYSE:PFE traded down $1.18 during mid-day trading on Monday, hitting $51.94. The company had a trading volume of 757,527 shares, compared to its average volume of 32,363,008. Pfizer Inc. has a fifty-two week low of $37.96 and a fifty-two week high of $61.71. The business’s fifty day moving average is $50.95 and its two-hundred day moving average is $50.98. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.19 and a current ratio of 1.40. The firm has a market cap of $293.35 billion, a P/E ratio of 13.76, a P/E/G ratio of 0.77 and a beta of 0.77.

Pfizer (NYSE:PFEGet Rating) last released its earnings results on Tuesday, February 8th. The biopharmaceutical company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.23. The firm had revenue of $23.84 billion for the quarter, compared to analyst estimates of $24.20 billion. Pfizer had a return on equity of 34.53% and a net margin of 26.97%. The company’s quarterly revenue was up 104.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Equities analysts forecast that Pfizer Inc. will post 7.28 earnings per share for the current year.

Several research analysts have recently issued reports on PFE shares. Citigroup upped their target price on shares of Pfizer from $46.00 to $57.00 and gave the company a “neutral” rating in a report on Tuesday, April 5th. Zacks Investment Research cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $52.00 price target on the stock. in a research note on Tuesday, February 15th. Mizuho decreased their price target on shares of Pfizer from $56.00 to $55.00 in a research note on Thursday, February 10th. Sanford C. Bernstein increased their price objective on shares of Pfizer from $44.00 to $65.00 and gave the stock a “market perform” rating in a report on Monday, January 3rd. Finally, BMO Capital Markets raised their price target on shares of Pfizer from $60.00 to $76.00 in a report on Friday, January 14th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $58.00.

About Pfizer (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

See Also

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFEGet Rating).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.